I-Mab Announces IND Approval by FDA for Phase 1 Study for Alzheimer's Treatment

 

• Planning underway for a Phase 1 Trial to assess new immunotherapy aimed at stimulating the innate immune system to clear beta amyloid protein plaques in Alzheimer's Disease

 I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) submission for Protollin, an investigational drug to treat Alzheimer's disease, enabling a Phase 1 clinical trial to be initiated. Worldwide, around 50 million people are living with Alzheimer's disease or other dementias, with no cure available.

https://www.gurufocus.com/news/1488854/imab-announces-ind-approval-by-fda-to-initiate-phase-1-study-for-protollin-for-the-treatment-of-alzheimers-disease